Abstract:Background: To investigate the risk factors for the development of pulmonary arterial hypertension (PAH) in patients with systemic lupus erythematosus (SLE). Methods: The literature related to risk factors for the development of PAH in SLE patients was searched by the computer on China national knowledge infrastructure (CNKI), PubMed, and Embase, and the literature search was limited to the period of library construction to October 2022. Two researchers independently performed literature screening and literature information extracting, including first author, publication time, case collection time, sample size, and study factors, and used the Newcastle-Ottawa Scale (NOS) to evaluate the quality of the literature. The relationship between each clinical manifestation and laboratory index and the occurrence of PAH in SLE patients was evaluated based on the ratio (OR value) and its 95% CI. Results: A total of 24 publications were included, including 23 case-control studies and 1 cohort study with NOS ≥ 6, and the overall quality of the literature was high. The risk of PAH was higher in SLE patients who developed Raynaud phenomenon than in those who did not [OR = 2.39, 95% CI (1.91, 2.99), P < .05]; the risk of PAH was higher in SLE patients who were positive for anti-RNP antibodies than in those who were negative for anti-RNP antibodies [OR = 1.77, 95% CI (1.17, 3.2.65), P < .05]; the risk of PAH was higher in SLE patients with interstitial lung lesions than in those without combined interstitial lung lesions [OR = 3.28, 95% CI (2.37, 4.53), P < .05]; the risk of PAH was higher in SLE patients with combined serositis than in those without serositis [OR = 2.28, 95% CI (1.83, 2.84), P < .05]. The risk of PAH was higher in SLE patients with combined pericardial effusion than in those without pericardial effusion [OR = 2.97, 95% CI (2.37, 3.72), P < .05]; the risk of PAH was higher in SLE patients with combined vasculitis than in those without vasculitis [OR = 1.50, 95% CI (1.08, 2.07), P < .05]; rheumatoid factor-positive SLE patients had a higher risk of PAH than those with rheumatoid factor-negative [OR = 1.66, 95% CI (1.24, 2.24), P < .05]. Conclusion: Raynaud phenomenon, vasculitis, anti-RNP antibodies, serositis, interstitial lung lesions, rheumatoid factor, and pericardial effusion are risk factors for the development of PAH in patients with SLE.

The LPS Induced Pyroptosis Exacerbates BMPR2 Signaling Deficiency to Potentiate SLE‐PAH

Cathepsin L Promotes Pulmonary Hypertension via BMPR2/GSDME-Mediated Pyroptosis

Cathepsin S Inhibition Suppresses Experimental Systemic Lupus Erythematosus-Associated Pulmonary Arterial Remodeling

Adverse effects of BMPR2 suppression in macrophages in animal models of pulmonary hypertension

Systemic lupus erythematosus associated pulmonary arterial hypertension: results from 10-year inpatient cases analysis in a single center

E3 ligase FBXW7 aggravates TMPD-induced systemic lupus erythematosus by promoting cell apoptosis

Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Based on a CSTAR-PAH Study: Baseline Characteristics and Risk Factors

Exacerbated inflammatory signaling underlies aberrant response to BMP9 in pulmonary arterial hypertension lung endothelial cells

Circulating extracellular vesicles as novel biomarkers for pulmonary arterial hypertension in patients with systemic lupus erythematosus

Circulating microvesicles as novel biomarkers for pulmonary arterial hypertension in patients with systemic lupus erythematosus

The small molecule macrophage migration inhibitory factor antagonist MIF098, inhibits pulmonary hypertension associated with murine SLE

Risk factors of pulmonary arterial hypertension in patients with systemic lupus erythematosus: A meta-analysis

Pulmonary hypertension secondary to systemic lupus erythematosus: a 2 years follow-up of 35 cases

Risk factors of systemic lupus erythematosus patients with pulmonary arterial hypertension: A systematic review and meta-analysis

Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Current Status and Future Direction

Predictive Factors for Concomitant Pulmonary Arterial Hypertension at Diagnosis of Systemic Lupus Erythematosus in a Chinese Population

Quantitative proteomic analysis and replacement therapy identifies haptoglobin as a therapeutic target in a murine model of SLE-associated diffuse alveolar hemorrhage

Severe Pulmonary Arterial Hypertension Secondary To Lupus In The Emergency Department: Proactive Intense Care Associated With A Better Short-Term Survival

Two distinct clinical phenotypes of pulmonary arterial hypertension secondary to systemic lupus erythematosus.

Cysteine-rich Protein 61 As a Novel Biomarker in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension

Clinical Analysis of Systemic Lupus Erythematosus Complicating Pulmonary Hypertension in 37 Cases